Fred Saad, MD, discusses the findings of ACIS, a phase 3 clinical trial of apalutamide and abiraterone acetate plus prednisone vs abiraterone alone for chemotherapy-naive CRPC.
Kohei Shitara, MD, National Cancer Center Hospital East, Kashiwa, Japan, discusses trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer, an approval based on results…
Dr Cervantes highlights the significance of the DESTINY-Gastric01 trial and discusses new advancements in the treatment of HER2+ gastric cancer.
Jan A. Burger, MD, PhD, MD Anderson Cancer Center, discusses "Outcomes of First-Line Ibrutinib in Patients with CLL/SLL and High-Risk Genomic Features with up to 6.5 Years Follow-up: Integrated…
Dr Linden shares encouraging results from the AMEERA-1 trial of SAR439859 for ER+/HER2- metastatic breast cancer, presented at the virtual 2020 SABCS Annual Meeting.
In this podcast, Dr Hochhaus discusses the significance of the ASCEMBL trial, and proposes the question of how to eliminate persisting leukemic stem cells (LSCs) in CML.
Dr Hochhaus discusses the use of asciminib versus bosutinib for the treatment of patients with CML-CP previously given ≥2 TKIs.
In this podcast, Dr Raje discusses the clinical significance of anti-BCMA CAR-T therapy with bb2121 in patients with relapsed or refractory MM.
Stay in the know.
OncNet Newsletter